Computer-Designed Peptide Vaccine Against Antibiotic-Resistant Brevundimonas Bacteria
Researchers used computational methods to design a multi-epitope peptide vaccine targeting essential proteins of the antibiotic-resistant pathogen Brevundimonas subvibrioides.
Quick Facts
What This Study Found
A multi-epitope vaccine candidate was designed using subtractive proteomics and immunoinformatics targeting essential hypothetical proteins of antibiotic-resistant B. subvibrioides.
Key Numbers
15 essential hypothetical proteins from DEG database. Multi-server functional annotation, physicochemical characterization, and non-homology analysis performed.
How They Did This
In silico study combining subtractive proteomics (to identify essential non-human-homologous bacterial proteins) with immunoinformatics (to predict immunogenic epitopes and design a multi-epitope vaccine construct).
Why This Research Matters
Antibiotic resistance is rendering current treatments ineffective against Brevundimonas infections. A vaccine approach could prevent infections entirely, bypassing the resistance problem.
The Bigger Picture
This work exemplifies how computational vaccinology can accelerate vaccine design against emerging antibiotic-resistant pathogens, potentially shortening the path from target identification to candidate selection.
What This Study Doesn't Tell Us
Entirely computational — no laboratory validation, animal testing, or clinical data. The predicted immunogenicity and protective efficacy remain theoretical until experimentally confirmed.
Questions This Raises
- ?Will the computationally designed vaccine candidate produce the predicted immune response in laboratory and animal studies?
- ?Can this in silico pipeline be applied to other antibiotic-resistant pathogens?
Trust & Context
- Key Stat:
- Entirely in silico design The vaccine was designed using computational proteomics and immunoinformatics without any laboratory experiments
- Evidence Grade:
- Computational study only — no experimental validation. Represents the earliest stage of vaccine development and requires extensive laboratory and clinical testing before any conclusions about real-world efficacy.
- Study Age:
- Published in 2025, using current bioinformatics tools for vaccine design against an emerging pathogen.
- Original Title:
- An in silico vaccinomics strategy to develop multiepitope vaccine using essential hypothetical protein as a target against Brevundimonas subvibrioides: A combined subtractive proteomics and immunoinformatics approach.
- Published In:
- Microbial pathogenesis, 205, 107651 (2025)
- Authors:
- Paul, Ishani, Roy, Alankar, Sarkar, Tista, Dutta, Shounak, Ray, Sujay
- Database ID:
- RPEP-12989
Evidence Hierarchy
Frequently Asked Questions
What is a multi-epitope vaccine?
A multi-epitope vaccine contains multiple small protein fragments (epitopes) from a pathogen, designed to activate different parts of the immune system. This approach can provide broader protection than targeting a single protein.
What is Brevundimonas and why does it need a vaccine?
Brevundimonas subvibrioides is an opportunistic bacterium found in urinary tract infections and mastitis. It has become resistant to multiple antibiotics, making vaccination a potential alternative strategy to prevent infections.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12989APA
Paul, Ishani; Roy, Alankar; Sarkar, Tista; Dutta, Shounak; Ray, Sujay. (2025). An in silico vaccinomics strategy to develop multiepitope vaccine using essential hypothetical protein as a target against Brevundimonas subvibrioides: A combined subtractive proteomics and immunoinformatics approach.. Microbial pathogenesis, 205, 107651. https://doi.org/10.1016/j.micpath.2025.107651
MLA
Paul, Ishani, et al. "An in silico vaccinomics strategy to develop multiepitope vaccine using essential hypothetical protein as a target against Brevundimonas subvibrioides: A combined subtractive proteomics and immunoinformatics approach.." Microbial pathogenesis, 2025. https://doi.org/10.1016/j.micpath.2025.107651
RethinkPeptides
RethinkPeptides Research Database. "An in silico vaccinomics strategy to develop multiepitope va..." RPEP-12989. Retrieved from https://rethinkpeptides.com/research/paul-2025-an-in-silico-vaccinomics
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.